| NICE Issues Guidelines for Diagnosis, Treatment of Advanced Breast
For patients who are receiving treatment with trastuzumab for advanced breast cancer, discontinue treatment with trastuzumab at the time of disease progression outside the central nervous system. Do not discontinue trastuzumab if disease progression is within the central nervous system alone.
� A breast cancer multidisciplinary team should assess all patients presenting with uncontrolled local disease and discuss the therapeutic options for controlling the disease and relieving symptoms.
� Consider offering bisphosphonates to patients newly diagnosed with bone metastases, to prevent skeletal-related events and reduce pain.
� Offer surgery followed by whole brain radiotherapy to patients who have a single or small number of brain metastases that could potentially be removed by surgery, a good performance status, and who have no or well-controlled other metastatic disease.
Surrender Monkey Friday: Nationalized Health Care Is Killer, Man!
The Government's rationing body said two drugs for advanced breast cancer and a rare form of stomach cancer were too expensive for the NHS. The National Institute for Health and Clinical Excellence is expected to confirm guidance in the next few weeks that will effectively ban their use. Well, we see how it is done in Great Britain. It's just too darn expensive to be humane to people who are suffering. But, on the bright side, we will all be waiting in long lines, allowing our symptoms to become worse, like in Britain, Canada, and France, among others, if nationalized health care is imposed. Not to mention having our 4th Amendment Rights violated constantly. » Filed Under 4th Amendment, Anti-Capitalism, Barack Obama, Communism, Dems In Charge: Now What?, Europe, Government ethics/corruption, Healthcare, News, Socialism, Surrender Monkey Friday, U.S.
Herceptin proven to benefit women with HER2 positive early breast
Herceptin has demonstrated unprecedented efficacy in treating both early and advanced (metastatic) HER2 positive breast cancer. Given on its own as monotherapy as well as in combination with or following standard chemotherapy, Herceptin has been shown to improve response rates, disease-free survival and overall survival while maintaining quality of life in women with HER2 positive breast cancer. Herceptin received approval for use in the European Union for advanced (metastatic) HER2 positive breast cancer in 2000, and for early (adjuvant) HER2 positive breast cancer in 2006. In the advanced (metastatic) setting, Herceptin is approved for use as a first-line therapy in combination with paclitaxel where anthracyclines are unsuitable, as first-line therapy in combination with docetaxel, and as a single agent in third-line therapy.
Clarient Renews and Expands Mezzanine Credit Facility With Safeguard
Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and diagnostic services available both onsite and over the web. The Company is also developing new, proprietary "companion" diagnostic markers for therapeutics in breast, prostate, lung and colon cancers, and leukemia/lymphoma. Clarient is a Safeguard Scientifics, Inc. partner company. www.clarientinc.com About Safeguard Founded in 1953 and based in Wayne, PA, Safeguard Scientifics, Inc. (NYSE: SFE) provides growth capital for entrepreneurial and innovative technology and life sciences companies. Safeguard targets technology companies in Software as a Service (SaaS) / Internet-based Businesses, Technology-Enabled Services and Vertical Software Solutions, and life sciences companies in Molecular and Point-of-Care Diagnostics, Medical Devices and Specialty Pharmaceuticals with capital requirements between $5 and $50 million.
Patients will be able to get cancer drug on the NHS
Pat Cooke, 76, from Hanover Square, Feering, started a trial of the drug in 2007 after she was diagnosed with breast cancer. She has praised the drug, created by GlaxoSmithKline, saying it allowed her to carry on with her normal life. The National Institute for Health and Clinical Excellence has advised against the medication being used in patients with advanced breast cancer, but NHS North East Essex said formal guidelines have not yet been issued. Mary Tompkins, assistant director of medicine management at NHS North East Essex, said she could not comment on individual cases. She said: “However, any person who has taken part in a national clinical trial of a drug which has not received approval by National Institute for Health and Clinical Excellence, would normally expect to receive any ongoing treatment needed with that drug as part of the trial through a hospital consultant.
Girls put your boots on
“Being diagnosed with advanced breast cancer in September 2007, I know full well how important it is to have these quality nurses on hand," Wells said. Interested players can contact Wells by phone call or sms on 0405 245 569 or email jenny.wells@live.com.au. .
All for Anthony
Tamarraw (Tam-a-raw) discovered she had advanced breast cancer four years after Tony was diagnosed. Anthony was in the sixth grade at the time. He had developed a close bond with his mother but wasn't old enough to fully understand the severity of her situation. "He would say to me, 'You don't look sick,' " Tamarraw said. Tamarraw had surgery and underwent a clinical trial stem cell procedure at Stanford Hospital, where she was exposed to lethal doses of radiation that brought her white cell blood count to zero. A stem cell that had been removed from her body was frozen and re-inserted. "Even during all that there was a treadmill outside my room," Tamarraw said. "I would get on the treadmill and take walks on the campus for exercise." Tony did his best to maintain some semblance of normalcy during Tamarraw's ordeal.
Bionovo Announces 2008 Highlights and Year-End Financial Results
Results from a second clinical study of BZL101 in advanced breast cancer was presented at ASCO, indicating BZL101's favorable tolerability and safety profile, and exhibiting encouraging signs of positive efficacy. Further results from this study were presented to the Society of Integrative Oncology (SIO), where the abstract was the highest scoring abstract. Additional studies of BN107 and BN108 were presented at the San Antonio Breast Cancer Symposium, indicating promising signs of potential efficacy for both cancer drug candidates. VG101 Laboratory studies were presented at the 7th Annual Oxford International Conference on the Science of Botanicals & American Society of Pharmacognosy 4th Interim Meeting, describing the structural elucidation of active estrogen receptor beta selective compounds from VG101, Bionovo's drug candidate for vaginal atrophy.
Pancreatic Cancer News You Can't Use
Women who learn that they carry gene variations that increase their risk of breast cancer can consider prophylactic mastectomy. Even the recent news that moderate drinking raises pancreatic cancer risk is actionable: you can cut back on your alcohol consumption. But what if you have Type B blood? Should you have your pancreas removed -- thus inducing life-long diabetes -- just in case? Experts would agree: Of course not, especially because the new findings' implications aren't yet fully understood. In fact, the study's authors acknowledge that this new information is practically useless in a clinical sense right now but may help scientists develop much-needed screening tests for pancreatic cancer. One of the reasons the disease kills nearly all its victims (more than 34,000 of them a year in the U.S.) so quickly is that it's famously hard to detect until it's too advanced for treatment to make a difference.
Pharmacyclics, Inc. Announces Closing of a Private Financing With
Pharmacyclics currently has four drugs in Phase I to Phase III clinical development for cancer. This includes a leading histone deacetylase inhibitor (PCI-24781) for multiple cancers; an inhibitor of Factor VIIa (PCI-27483) targeting pancreatic, gastric, colon and breast cancers; a first in class inhibitor of Bruton's tyrosine kinase (Btk) (PCI-32765) currently in a Phase I clinical trial and targeting B-cell related oncology applications; a Btk inhibitor in advanced preclinical testing (PCI-45261) targeting autoimmune and allergic indications; and an HDAC-8 inhibitor (PCI-34051) for autoimmune and cancer indications. Motexafin gadolinium (MGd) has completed two Phase III trials in patients with brain metastases from non-small-cell lung cancer (NSCLC) and other cancers and is currently in a Phase II trial for glioblastoma.
|
